Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 9/20 | 0.46 |
| ▸ | GLP1R | P43220 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | USP5 | P45974 | 1/20 | 0.42 |
| ▸ | GIPR | P48546 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | GCG | P01275 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651641 | 0.93 | PPARD (0.47) | GCGRGLP1RPPARDGIPRGCG | |
| SCHEMBL2652188 | 0.93 | PPARD (0.47) | GCGRGLP1RPPARDGIPRGCG | |
| SCHEMBL2647399 | 0.93 | PPARD (0.47) | GCGRGLP1RPPARDGIPRGCG | |
| SCHEMBL2655420 | 0.92 | PPARD (0.47) | GCGRGLP1RPPARDGIPRGCG | |
| SCHEMBL2665073 | 0.88 | GCGR (0.43) | GCGRGLP1RPPARDGIPRGCG | |
| SCHEMBL2660535 | 0.88 | GCGR (0.43) | GCGRGLP1RPPARDGIPRGCG | |
| SCHEMBL2655272 | 0.88 | ALDH1A1 (0.47) | GCGRGLP1RGCG | |
| SCHEMBL2653731 | 0.87 | HAO1 (0.46) | GCGRPPARDCYP2D6 | |
| SCHEMBL2662324 | 0.85 | GCGR (0.51) | GCGRGLP1RGCG | |
| SCHEMBL6917620 | 0.85 | GCGR (0.51) | GCGRGLP1RGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152750-A1 | Novel glucagon antagonists | NOVO NORDISK A/S (DK) | 2004-08-05 | — | — | US | disclosed |
| WO-2004056763-A2 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056763-A2 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152750-A1 | Novel glucagon antagonists | GLP1R, GCGR, GIPR | GCGR 2/4885GLP1R 1/4885PPARD 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.